Newleos Therapeutics is a clinical-stage biotechnology company co-founded by Longwood Fund and seasoned CNS drug-development leaders, headquartered in Boston, Massachusetts. Its pipeline, licensed from Roche, develops oral small-molecule therapeutics targeting GABAA-gamma1, V1a, TAAR1 and GABAA-alpha5 mechanisms, with first- or best-in-class… - View it on GitHub